SE0403006D0 - New compounds - Google Patents
New compoundsInfo
- Publication number
- SE0403006D0 SE0403006D0 SE0403006A SE0403006A SE0403006D0 SE 0403006 D0 SE0403006 D0 SE 0403006D0 SE 0403006 A SE0403006 A SE 0403006A SE 0403006 A SE0403006 A SE 0403006A SE 0403006 D0 SE0403006 D0 SE 0403006D0
- Authority
- SE
- Sweden
- Prior art keywords
- sup
- compounds
- new compounds
- prophylaxis
- obesity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0403006A SE0403006D0 (sv) | 2004-12-09 | 2004-12-09 | New compounds |
| US11/296,928 US20060142269A1 (en) | 2004-12-09 | 2005-12-08 | New compounds |
| PCT/SE2005/001885 WO2006062481A1 (en) | 2004-12-09 | 2005-12-09 | New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0403006A SE0403006D0 (sv) | 2004-12-09 | 2004-12-09 | New compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE0403006D0 true SE0403006D0 (sv) | 2004-12-09 |
Family
ID=33550628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0403006A SE0403006D0 (sv) | 2004-12-09 | 2004-12-09 | New compounds |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US20060142269A1 (sv) |
| SE (1) | SE0403006D0 (sv) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7842713B2 (en) * | 2006-04-20 | 2010-11-30 | Pfizer Inc | Fused phenyl amido heterocyclic compounds |
| NZ591366A (en) | 2008-09-11 | 2012-05-25 | Pfizer | Heteroaryls amide derivatives and their use as glucokinase activators |
| EP2406253B1 (en) | 2009-03-11 | 2013-07-03 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
| EP3091021B1 (en) * | 2009-10-26 | 2019-08-28 | Signal Pharmaceuticals, LLC | Methods of synthesis and purification of heteroaryl compounds |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| KR101893751B1 (ko) | 2010-07-16 | 2018-09-03 | 애브비 아일랜드 언리미티드 컴퍼니 | 항바이러스성 화합물의 제조 방법 |
| BR112013001138A2 (pt) | 2010-07-16 | 2016-07-05 | Abbvie Inc | ligantes de fosfina para reações catalíticas |
| TWI708605B (zh) | 2011-10-19 | 2020-11-01 | 標誌製藥公司 | 以ｔｏｒ激酶抑制劑治療癌症 |
| EA026390B1 (ru) | 2011-12-02 | 2017-04-28 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ 7-(6-(2-ГИДРОКСИПРОПАН-2-ИЛ)ПИРИДИН-3-ИЛ)-1-((ТРАНС)-4-МЕТОКСИЦИКЛОГЕКСИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА, ИХ ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| EP2817029B1 (en) | 2012-02-24 | 2019-07-10 | Signal Pharmaceuticals, LLC | Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| US9346812B2 (en) | 2013-01-16 | 2016-05-24 | Signal Pharmaceuticals, Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| CA2908830C (en) | 2013-04-17 | 2021-12-07 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| MX2015014455A (es) | 2013-04-17 | 2016-07-21 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer. |
| EP2986321A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
| AU2014253978B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and a 5-Substituted Quinazolinone Compound for treating cancer |
| NZ629230A (en) | 2013-04-17 | 2017-05-26 | Signal Pharm Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| NZ629332A (en) | 2013-04-17 | 2017-05-26 | Signal Pharm Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| CA2908957C (en) | 2013-04-17 | 2021-05-18 | Signal Pharmaceuticals, Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| JP6401250B2 (ja) | 2013-05-29 | 2018-10-10 | シグナル ファーマシューティカルズ，エルエルシー | ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法 |
| US9737535B2 (en) | 2014-04-16 | 2017-08-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
| WO2015160882A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2015160880A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| US9623028B2 (en) | 2014-07-14 | 2017-04-18 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| WO2017083488A1 (en) * | 2015-11-11 | 2017-05-18 | Warner Babcock Institute for Green Chemistry | Benzofuran derivatives for the treatment of cns and other disorders |
| BR112019027402A2 (pt) | 2017-06-22 | 2020-07-07 | Celgene Corporation | tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b |
-
2004
- 2004-12-09 SE SE0403006A patent/SE0403006D0/sv unknown
-
2005
- 2005-12-08 US US11/296,928 patent/US20060142269A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20060142269A1 (en) | 2006-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE0403006D0 (sv) | New compounds | |
| PT1902037E (pt) | 2,4-diamino-pirimidinas como inibidores de aurora | |
| GEP20125565B (en) | Lactam compounds and their pharmaceutical use | |
| MY143390A (en) | Sulfonamide derivatives for the treatment of diseases. | |
| MY139690A (en) | Sulfonamide derivatives for the treatment of diseases. | |
| NO20064325L (no) | Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes | |
| ATE384058T1 (de) | Thiazolderivate | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
| GB0625648D0 (en) | Compounds | |
| IL196543A (en) | Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders | |
| MX2008002061A (es) | Derivados de tiazolil piperidina utiles como moduladores del receptor h3. | |
| EA200801997A1 (ru) | Новые соединения | |
| EA200601462A1 (ru) | Соединения для лечения заболеваний | |
| MX2007011695A (es) | Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos. | |
| SE0300119D0 (sv) | Novel compounds | |
| EA201070423A1 (ru) | Диарильные соединения оксадиазолов | |
| EP1689713A4 (en) | BENZYLETHER AND BETA-SECRETASE BENZYLAMINO INHIBITORS FOR TREATING ALZHEIMER'S DISEASE | |
| EP1817312A4 (en) | MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| DE602006010738D1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| MX2007011698A (es) | Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos. | |
| GB0524814D0 (en) | Compounds | |
| TW200745081A (en) | Compounds | |
| TW200505865A (en) | Compounds useful for the treatment of diseases | |
| MXPA05004621A (es) | Derivados de anilinopirazol utiles en el tratamiento de la diabetes. |